361 related articles for article (PubMed ID: 21539904)
1. N-terminal specificity of PEGylation of human bone morphogenetic protein-2 at acidic pH.
Hu J; Sebald W
Int J Pharm; 2011 Jul; 413(1-2):140-6. PubMed ID: 21539904
[TBL] [Abstract][Full Text] [Related]
2. Site-specific PEGylation of bone morphogenetic protein-2 cysteine analogues.
Hu J; Duppatla V; Harth S; Schmitz W; Sebald W
Bioconjug Chem; 2010 Oct; 21(10):1762-72. PubMed ID: 20886828
[TBL] [Abstract][Full Text] [Related]
3. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
[TBL] [Abstract][Full Text] [Related]
4. The influence of covalently linked and free polyethylene glycol on the structural and release properties of rhBMP-2 loaded microspheres.
Lochmann A; Nitzsche H; von Einem S; Schwarz E; Mäder K
J Control Release; 2010 Oct; 147(1):92-100. PubMed ID: 20603166
[TBL] [Abstract][Full Text] [Related]
5. Polyethylenimine-PEG coated albumin nanoparticles for BMP-2 delivery.
Zhang S; Kucharski C; Doschak MR; Sebald W; Uludağ H
Biomaterials; 2010 Feb; 31(5):952-63. PubMed ID: 19878992
[TBL] [Abstract][Full Text] [Related]
6. Solid-phase N-terminus PEGylation of recombinant human fibroblast growth factor 2 on heparin-sepharose column.
Huang Z; Ye C; Liu Z; Wang X; Chen H; Liu Y; Tang L; Zhao H; Wang J; Feng W; Li X
Bioconjug Chem; 2012 Apr; 23(4):740-50. PubMed ID: 22433083
[TBL] [Abstract][Full Text] [Related]
7. Analysis of hydrolyzable polyethylene glycol hydrogels and deproteinized bone mineral as delivery systems for glycosylated and non-glycosylated bone morphogenetic protein-2.
Hänseler P; Jung UW; Jung RE; Choi KH; Cho KS; Hämmerle CH; Weber FE
Acta Biomater; 2012 Jan; 8(1):116-23. PubMed ID: 21867781
[TBL] [Abstract][Full Text] [Related]
8. Protein carboxyl amidation increases the potential extent of protein polyethylene glycol conjugation.
Li S; Yang Z; Sun X; Tan Y; Yagi S; Hoffman RM
Anal Biochem; 2004 Jul; 330(2):264-71. PubMed ID: 15203332
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate-coated BSA nanoparticles lack bone targeting after systemic administration.
Wang G; Kucharski C; Lin X; Uludağ H
J Drug Target; 2010 Sep; 18(8):611-26. PubMed ID: 20158316
[TBL] [Abstract][Full Text] [Related]
10. Emissive behavior, cytotoxic activity, cellular uptake, and PEGylation properties of new luminescent rhenium(I) polypyridine poly(ethylene glycol) complexes.
Choi AW; Louie MW; Li SP; Liu HW; Chan BT; Lam TC; Lin AC; Cheng SH; Lo KK
Inorg Chem; 2012 Dec; 51(24):13289-302. PubMed ID: 23198846
[TBL] [Abstract][Full Text] [Related]
11. Aldehyde PEGylation kinetics: a standard protein versus a pharmaceutically relevant single chain variable fragment.
Moosmann A; Blath J; Lindner R; Müller E; Böttinger H
Bioconjug Chem; 2011 Aug; 22(8):1545-58. PubMed ID: 21780828
[TBL] [Abstract][Full Text] [Related]
12. Chemical and enzymatic site specific PEGylation of hGH.
da Silva Freitas D; Mero A; Pasut G
Bioconjug Chem; 2013 Mar; 24(3):456-63. PubMed ID: 23432141
[TBL] [Abstract][Full Text] [Related]
13. Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12).
Youn YS; Lee KC
Bioconjug Chem; 2007; 18(2):500-6. PubMed ID: 17243755
[TBL] [Abstract][Full Text] [Related]
14. PEG chain length impacts yield of solid-phase protein PEGylation and efficiency of PEGylated protein separation by ion-exchange chromatography: insights of mechanistic models.
Yoshimoto N; Isakari Y; Itoh D; Yamamoto S
Biotechnol J; 2013 Jul; 8(7):801-10. PubMed ID: 23788446
[TBL] [Abstract][Full Text] [Related]
15. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and characterization of chitosan-g-poly(ethylene glycol)-folate as a non-viral carrier for tumor-targeted gene delivery.
Chan P; Kurisawa M; Chung JE; Yang YY
Biomaterials; 2007 Jan; 28(3):540-9. PubMed ID: 16999995
[TBL] [Abstract][Full Text] [Related]
17. Interactions between PEG and type I soluble tumor necrosis factor receptor: modulation by pH and by PEGylation at the N terminus.
Kerwin BA; Chang BS; Gegg CV; Gonnelli M; Li T; Strambini GB
Protein Sci; 2002 Jul; 11(7):1825-33. PubMed ID: 12070334
[TBL] [Abstract][Full Text] [Related]
18. C-terminal site-specific PEGylation of a truncated thrombomodulin mutant with retention of full bioactivity.
Cazalis CS; Haller CA; Sease-Cargo L; Chaikof EL
Bioconjug Chem; 2004; 15(5):1005-9. PubMed ID: 15366953
[TBL] [Abstract][Full Text] [Related]
19. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.
Yoshioka Y; Tsutsumi Y; Ikemizu S; Yamamoto Y; Shibata H; Nishibata T; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Nagata S; Yamagata Y; Mayumi T
Biochem Biophys Res Commun; 2004 Mar; 315(4):808-14. PubMed ID: 14985084
[TBL] [Abstract][Full Text] [Related]
20. Transglutaminase-mediated PEGylation of proteins: direct identification of the sites of protein modification by mass spectrometry using a novel monodisperse PEG.
Mero A; Spolaore B; Veronese FM; Fontana A
Bioconjug Chem; 2009 Feb; 20(2):384-9. PubMed ID: 19186937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
